Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Vincenzo Savarino, Luca Antonioli, Matteo Fornai, Elisa Marabotto, Maria Giulia Demarzo, Fabiana Zingone, Matteo Ghisa, Brigida Barberio, Patrizia Zentilin, Mentore Ribolsi & Edoardo Savarino. (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Review of Gastroenterology & Hepatology 16:5, pages 401-410.
Read now
Read now
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli & Edoardo Savarino. (2017) Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy 18:11, pages 1145-1152.
Read now
Read now
Edoardo Savarino, Irene Martinucci, Manuele Furnari, Chiara Romana, Gaia Pellegatta, Alessandro Moscatelli, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Nicola de Bortoli & Corrado Blandizzi. (2016) Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1333-1341.
Read now
Read now
Michael Herrmann, Jens Selige, Sandra Raffael, George Sachs, Andrea Brambilla & Thomas Klein. (2007) Systematic expression profiling of the gastric H+/K+ ATPase in human tissue. Scandinavian Journal of Gastroenterology 42:11, pages 1275-1288.
Read now
Read now
Articles from other publishers (50)
Myeongjoong Kim, Bongtae Kim, Ju-Hyun Lee, Donghyun Kim, Geun Seog Song, Scott D. Williams & Woo-Chan Son. (2023) Carcinogenicity assessment of tegoprazan in Sprague-Dawley (Crl:CD) rats and ICR (Crl:CD1) mice. Regulatory Toxicology and Pharmacology 142, pages 105424.
Crossref
Crossref
K Manimekalai, R Sudar Codi, Navinraja Komal Veererathinakumar & Vimala Ananthy. (2023) Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder. SBV Journal of Basic, Clinical and Applied Health Science 6:2, pages 33-38.
Crossref
Crossref
Inyoung Hwang, Sang Chun Ji, Jaeseong Oh, Hyojin Kim, Hyunju Cha, John Kim, Chang‐Seok Lee, Kyung‐Sang Yu & SeungHwan Lee. (2023) Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects. Alimentary Pharmacology & Therapeutics 57:7, pages 763-772.
Crossref
Crossref
Aleksandar Cvetkovic, Marko Spasic, Mladen Pavlovic, Danijela Cvetkovic, Bojan Stojanovic, Srdjan Ninkovic, Jasna Jevdjic, Dragan Canovic & Bojan Milosevic. (2022) The Use of Proton Pump Inhibitors in Intensive Care Units. Serbian Journal of Experimental and Clinical Research 23:3, pages 195-200.
Crossref
Crossref
Xianlian Wang, Yongmei Xu, Zaiwei Zong, Jinna Cai, Chunlin Chen, Qingwei Zhang, Xun Sun & Jianqi Li. (2022) Design, synthesis and biological evaluation of novel 5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as potent potassium-competitive acid blockers. Bioorganic & Medicinal Chemistry 64, pages 116765.
Crossref
Crossref
Jinjie He, Guoying Cao, Jicheng Yu, Jingjing Wang, Nengneng Cheng, Jufang Wu, Jing Zhang, Xiaojie Wu, Basheng Zhang, Jiayan Lu & Shangzhi Chen. (2020) Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. Clinical Drug Investigation 41:1, pages 89-97.
Crossref
Crossref
Masaki Murata, Mitsushige Sugimoto, Hitomi Mizuno, Takeshi Kanno & Kiichi Satoh. (2020) Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. Journal of Clinical Medicine 9:2, pages 543.
Crossref
Crossref
Kimitoshi Kubo, Noriko Kimura, Soichiro Matsuda, Momoko Tsuda, Katsuhiro Mabe & Mototsugu Kato. (2020) Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases. Internal Medicine 59:4, pages 507-511.
Crossref
Crossref
Enzo Ierardi, Giuseppe Losurdo, Rosa Federica La Fortezza, Mariabeatrice Principi, Michele Barone & Alfredo Di Leo. (2019)
Optimizing proton pump inhibitors in
Helicobacter pylori
treatment: Old and new tricks to improve effectiveness
. World Journal of Gastroenterology 25:34, pages 5097-5104.
Crossref
Crossref
Dong Kyu Kim, Keun-Ho Lee, Sung-jun Kim, Soo-Jin Kim, Song Jin Lee, Chi Hye Park, Bong-Tae Kim, Geun-Seog Song, Byoung-Seok Moon & Shin-Young Ryu. (2019) Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid–Related Disease. Journal of Pharmacology and Experimental Therapeutics 369:3, pages 318-327.
Crossref
Crossref
Yasuyoshi Arikawa. (2019) Synthetic Studies of Vonoprazan Fumarate, a Novel Potassium-Competitive Acid Blocker (P-CAB)新規カリウムイオン競合型アシッドブロッカー（P-CAB）ボノプラザンフマル酸塩の合成研究. Journal of Synthetic Organic Chemistry, Japan 77:3, pages 254-261.
Crossref
Crossref
Mitsushige Sugimoto & Yoshio Yamaoka. (2019) Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Frontiers in Pharmacology 9.
Crossref
Crossref
J. Sunwoo, J. Oh, S. J. Moon, S. C. Ji, S. H. Lee, K.-S. Yu, H. S. Kim, A. Lee & I.-J. Jang. (2018) Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Alimentary Pharmacology & Therapeutics 48:2, pages 206-218.
Crossref
Crossref
Tianyi Li, Hongqun Qiao, Peng Yue, Ming Cai & Xuejun He. (2018) Embryo–fetal toxicity assessment of vonoprazan in rats and rabbits. Journal of Applied Toxicology 38:7, pages 987-995.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
481
535
.
Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza & Yan-Qing Li. (2017) Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Digestive Diseases and Sciences 63:2, pages 302-311.
Crossref
Crossref
R. Rajesh, A. Manikandan, A. Sivakumar, C. Ramasubbu & N. Nagaraju. (2017) Substituted methoxybenzyl-sulfonyl- 1H -benzo[d]imidazoles evaluated as effective H + /K + -ATPase inhibitors and anti-ulcer therapeutics. European Journal of Medicinal Chemistry 139, pages 454-460.
Crossref
Crossref
Haruyuki Nishida, Yasuyoshi Arikawa, Keizo Hirase, Toshihiro Imaeda, Nobuhiro Inatomi, Yasunobu Hori, Jun Matsukawa, Yasushi Fujioka, Teruki Hamada, Motoo Iida, Mitsuyoshi Nishitani, Akio Imanishi, Hideo Fukui, Fumio Itoh & Masahiro Kajino. (2017) Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action. Bioorganic & Medicinal Chemistry 25:13, pages 3298-3314.
Crossref
Crossref
Xin Zhao, Xia Feng, Cun Wang, Deguang Peng, Kai Zhu & Jia-Le Song. (2017) Anticancer activity of Nelumbo nucifera stamen extract in human colon cancer HCT-116 cells in vitro. Oncology Letters 13:3, pages 1470-1478.
Crossref
Crossref
Chang Seok BangGwang Ho Baik. (2017)
Potassium-competitive Acid Blocker-based Therapy for
Helicobacter pylori
Eradication
. The Korean Journal of Gastroenterology 69:4, pages 263.
Crossref
Crossref
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai & Kazuyoshi Otake. (2016) Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics 168, pages 12-22.
Crossref
Crossref
Haruyuki Nishida. 2016. Successful Drug Discovery. Successful Drug Discovery
215
233
.
Yuko Akazawa, Daisuke Fukuda & Yutaka Fukuda. (2016)
Vonoprazan-based therapy for
Helicobacter pylori
eradication: experience and clinical evidence
. Therapeutic Advances in Gastroenterology 9:6, pages 845-852.
Crossref
Crossref
Kazuyoshi Otake, Yuuichi Sakurai, Haruyuki Nishida, Hideo Fukui, Yoshihiko Tagawa, Hitomi Yamasaki, Masatoshi Karashima, Keiichi Otsuka & Nobuhiro Inatomi. (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Advances in Therapy 33:7, pages 1140-1157.
Crossref
Crossref
T. Kagami, S. Sahara, H. Ichikawa, T. Uotani, M. Yamade, M. Sugimoto, Y. Hamaya, M. Iwaizumi, S. Osawa, K. Sugimoto, H. Miyajima & T. Furuta. (2016)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to
CYP
2C19 genotype
. Alimentary Pharmacology & Therapeutics 43:10, pages 1048-1059.
Crossref
Crossref
Hirotoshi Echizen. (2015) The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacokinetics 55:4, pages 409-418.
Crossref
Crossref
Jia-Le Song, Peng Sun, Rui Wang & Xin Zhao. (2015)
Gastroprotective Effects of Methanolic Extract of
S
terculia nobilis
Smith Seeds in Reserpine-Induced Gastric Ulcer in Mice
. Journal of Food Biochemistry 39:3, pages 230-237.
Crossref
Crossref
Jia-Le Song, Yalin Zhou, Xia Feng & Xin Zhao. (2015) White tea (Camellia sinenesis (L.)) ethanol extracts attenuate reserpine-induced gastric ulcers in mice. Food Science and Biotechnology 24:3, pages 1159-1165.
Crossref
Crossref
Yasuyoshi Arikawa, Atsushi Hasuoka, Haruyuki Nishida, Keizo Hirase, Nobuhiro Inatomi, Terufumi Takagi, Naoki Tarui, Makiko Kawamoto, Akio Imanishi, Fumio Itoh & Masahiro Kajino. (2015) Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs). Bioorganic & Medicinal Chemistry Letters 25:10, pages 2037-2040.
Crossref
Crossref
Jia-Le Song, Kai Zhu, Xia Feng & Xin Zhao. (2015) Protective effect Malus pumila Mill leaf polyphenols in reserpine-induced gastric ulcer in mice. Journal of the Korean Society for Applied Biological Chemistry 58:2, pages 249-256.
Crossref
Crossref
L N Rogoza & N F Salakhutdinov. (2015) Anti-ulcer agents: chemical aspect of solving the problem. Russian Chemical Reviews 84:1, pages 98-120.
Crossref
Crossref
Ahmed O.H. El-Nezhawy, Ayman R. Biuomy, Fatma S. Hassan, Ayman K. Ismaiel & Hany A. Omar. (2013) Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity. Bioorganic & Medicinal Chemistry 21:7, pages 1661-1670.
Crossref
Crossref
Yasuyoshi Arikawa, Haruyuki Nishida, Osamu Kurasawa, Atsushi Hasuoka, Keizo Hirase, Nobuhiro Inatomi, Yasunobu Hori, Jun Matsukawa, Akio Imanishi, Mitsuyo Kondo, Naoki Tarui, Teruki Hamada, Terufumi Takagi, Toshiyuki Takeuchi & Masahiro Kajino. (2012)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1
H
-pyrrol-3-yl]-
N
-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
. Journal of Medicinal Chemistry 55:9, pages 4446-4456.
Crossref
Crossref
Magda F. Morton, Terrance D. Barrett, Jamie Freedman, Lina Li, Michele C. Rizzolio, Clodagh E. Prendergast, Xiaodong Wu, Veronica Moreno, Jayashree Pyati, Katherine Figueroa, Laurence Cagnon, Guy Lagaud, Luc Ver Donck, Etienne Ghoos, Brett Allison, Michael H. Rabinowitz & Nigel P. Shankley. (2011)
JNJ-26070109 [(
R
)4-Bromo-
N
-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability
. Journal of Pharmacology and Experimental Therapeutics 338:1, pages 328-336.
Crossref
Crossref
Yasunobu Hori, Jun Matsukawa, Toshiyuki Takeuchi, Haruyuki Nishida, Masahiro Kajino & Nobuhiro Inatomi. (2011) A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals. Journal of Pharmacology and Experimental Therapeutics 337:3, pages 797-804.
Crossref
Crossref
Yasunobu Hori, Akio Imanishi, Jun Matsukawa, Yasuhiro Tsukimi, Haruyuki Nishida, Yasuyoshi Arikawa, Keizo Hirase, Masahiro Kajino & Nobuhiro Inatomi. (2010)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1
H
-pyrrol-3-yl]-
N
-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
. Journal of Pharmacology and Experimental Therapeutics 335:1, pages 231-238.
Crossref
Crossref
Andreas Marc Palmer & Antonio Zanotti-Gerosa. 2010. Asymmetric Catalysis on Industrial Scale. Asymmetric Catalysis on Industrial Scale
61
78
.
Neil Garton, Nick Bailey, Mark Bamford, Emmanuel Demont, Irene Farre-Gutierrez, Gail Hutley, Gianpaolo Bravi & Paula Pickering. (2010) Discovery of biaryl inhibitors of H+/K+ ATPase. Bioorganic & Medicinal Chemistry Letters 20:3, pages 1049-1054.
Crossref
Crossref
Nick Bailey, Mark J. Bamford, Delphine Brissy, Joanna Brookfield, Emmanuel Demont, Richard Elliott, Neil Garton, Irene Farre-Gutierrez, Thomas Hayhow, Gail Hutley, Antoinette Naylor, Terry A. Panchal, Hui-Xian Seow, David Spalding & Andrew K. Takle. (2009) Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs). Bioorganic & Medicinal Chemistry Letters 19:13, pages 3602-3606.
Crossref
Crossref
Andreas Marc Palmer, Sandra Chrismann, Gabriela Münch, Christof Brehm, Peter Jan Zimmermann, Wilm Buhr, Jörg Senn-Bilfinger, Martin Philipp Feth & Wolfgang Alexander Simon. (2009) Spiro(imidazo[1,2-a]pyrano[2,3-c]pyridine-9-indenes) as inhibitors of gastric acid secretion. Bioorganic & Medicinal Chemistry 17:1, pages 368-384.
Crossref
Crossref
Andreas M. Palmer, Matthias Webel, Christian Scheufler, Dieter Haag & Bernd Müller. (2008)
Large-Scale Asymmetric Synthesis of the 3,6,7,8-Tetrahydrochromeno[7,8-
d
]imidazole BYK 405879: A Promising Candidate for the Treatment of Acid-Related Diseases
. Organic Process Research & Development 12:6, pages 1170-1182.
Crossref
Crossref
M. Ravi Shashi Nayana, Y. Nataraja Sekhar, Haritha Nandyala, Ravikumar Muttineni, Santosh Kumar Bairy, Kriti Singh & S.K. Mahmood. (2008) Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies. Journal of Molecular Graphics and Modelling 27:3, pages 233-243.
Crossref
Crossref
Andreas Marc Palmer, Antonio Zanotti-Gerosa & Hans Nedden. (2008) Preparation of tricyclic imidazopyridines by asymmetric ketone hydrogenation in the presence of RuCl2[(S)-Xyl-P-Phos][(S)-DAIPEN]. Tetrahedron: Asymmetry 19:11, pages 1310-1327.
Crossref
Crossref
Peter Jan Zimmermann, Christof Brehm, Wilm Buhr, Andreas Marc Palmer, Jürgen Volz & Wolfgang-Alexander Simon. (2008) Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase. Bioorganic & Medicinal Chemistry 16:1, pages 536-541.
Crossref
Crossref
Peter J. Kahrilas, John Dent, Karsten Lauritsen, Peter Malfertheiner, Hans Denison, Stefan Franzén & Goran Hasselgren. (2007) A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis. Clinical Gastroenterology and Hepatology 5:12, pages 1385-1391.
Crossref
Crossref
Andreas Marc Palmer, Burkhard Grobbel, Christof Brehm, Peter Jan Zimmermann, Wilm Buhr, Martin Philipp Feth, Hans Christof Holst & Wolfgang Alexander Simon. (2007) Preparation of tetrahydroimidazo[2,1-a]isoquinolines and their use as inhibitors of gastric acid secretion. Bioorganic & Medicinal Chemistry 15:24, pages 7647-7660.
Crossref
Crossref
Andreas M. Palmer, Burkhard Grobbel, Cornelia Jecke, Christof Brehm, Peter J. Zimmermann, Wilm Buhr, Martin P. Feth, Wolfgang-Alexander Simon & Wolfgang Kromer. (2007)
Synthesis and Evaluation of 7
H
-8,9-Dihydropyrano[2,3-
c
]imidazo[1,2-
a
]pyridines as Potassium-Competitive Acid Blockers
. Journal of Medicinal Chemistry 50:24, pages 6240-6264.
Crossref
Crossref
Andreas M. Palmer & Ulrike Nettekoven. (2007) Preparation of tricyclic imidazopyridines by asymmetric ketone hydrogenation in the presence of ruthenium phosphino-oxazoline catalyst. Tetrahedron: Asymmetry 18:20, pages 2381-2385.
Crossref
Crossref
Peter Jan Zimmermann, Wilm Buhr, Christof Brehm, Andreas Marc Palmer, Martin Philipp Feth, Jörg Senn-Bilfinger & Wolfgang-Alexander Simon. (2007) Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase. Bioorganic & Medicinal Chemistry Letters 17:19, pages 5374-5378.
Crossref
Crossref
Jai Moo Shin & George Sachs. (2006) Gastric H,K-ATPase as a Drug Target. Digestive Diseases and Sciences 51:5, pages 823-833.
Crossref
Crossref